The elusive biomarker for personalized medicine in multiple sclerosis
The search continues
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
There are no objective methods or tests to predict the effectiveness of specific disease-modifying drugs (DMDs) for individual patients with multiple sclerosis (MS). There are 4 interferon-β (IFNβ) products and 4 non-IFNβ DMDs available for relapsing forms of MS, with others on the way. Randomized, placebo-controlled pivotal clinical trials showed that IFNβ drugs were only partially effective, reducing relapse rate by about 33%.1 While relapses or new MRI lesions are commonly observed in patients with MS on …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
Alert Me
Recommended articles
-
Article
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysisDavid Bargiela, Matthew T. Bianchi, M. Brandon Westover et al.Neurology, January 13, 2017 -
Articles
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MSS.E. Bushnell, Z. Zhao, C.C. Stebbins et al.Neurology, May 09, 2012 -
Views & Reviews
Natalizumab-associated PMLChallenges with incidence, resulting risk, and risk stratificationNicholas Schwab, Tilman Schneider-Hohendorf, Nico Melzer et al.Neurology, February 22, 2017 -
Articles
Multiple sclerosis pharmacogenomicsMaximizing efficacy of therapyDerek J. Pappas, Jorge R. Oksenberg et al.Neurology, December 28, 2009